ArticleMicrobiologyOpen2026
Facing Antimicrobial Resistance and Virulence in Streptococcus agalactiae During Late Pregnancy: Evaluation of Lactobacilli as a Supportive Approach.
Article in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Streptococcus agalactiae (Group B streptococcus, GBS) remains a major cause of neonatal sepsis and meningitis, despite the success of intrapartum antibiotic prophylaxis. However, the rising trend of antimicrobial resistance and the emergence of hypervirulent lineages highlight the need for complementary, innovative prophylactic strategies. This study aimed to characterize the resistance and virulence repertoire of colonizing GBS isolates and to assess the antagonistic potential of selected Lactobacillus strains under conditions mimicking the vaginal niche. We performed integrated phenotypic, genotypic, and functional analysis of 31 clinical GBS isolates collected during routine pre-partum screening, focusing on antimicrobial susceptibility, hemolytic and aggregation phenotypes, capsular serotypes, pilus island profiles, and virulence genes. The collection included MDR isolates, strains exhibiting inducible clindamycin resistance and high-level gentamicin resistance, as well as hypervirulent ST-17 related lineages, with marked heterogeneity in β-hemolytic activity and aggregation phenotypes linked to specific combinations of capsule, pilus, and virulence genes. In co-culture experiments with HeLa cells, individual Lactobacillus strains exerted strong, strain-dependent inhibition of GBS, preserving epithelial cell viability, and impairing pathogen adhesion by up to 98%. Importantly, the multi-strain Lactobacillus combination provided broader and more consistent antagonistic activity, including against MDR, inducible clindamycin-resistant, hypervirulent ST-17-associated, and strongly hemolytic GBS isolates. Although these findings are preliminary, being derived from a limited number of isolates and an in vitro model, they support the promising potential of rationally selected multi-strain Lactobacillus formulations as a strategy to reduce colonization by high-risk GBS lineages and warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.